Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Biotech startup Moderna&nbsp;became a leading contender in&nbsp;the production of Covid-19 vaccines last year in November&nbsp;as the&nbsp;results of clinical trials revealed that the vaccine was 94.1% effective in Phase 3 trials.With Indian drug regulator giving its nod for the emergency use of vaccine in the country, here are five facts one should know before considering the Moderna&nbsp;vaccine as an option.&nbsp;The vaccine developed&nbsp;by Moderna is an mRNA vaccine, which works differently than a typical vaccine. Instead of preventing infection, the vaccine works to teach the body to better fight the virus, lessening its severity.
Even if the 94.5% efficacy rating, a concern with any vaccine is safety. For Moderna&rsquo;s Covid-19 vaccine, early safety signs are good. Of the participants examined, there have been no major safety concerns reported.&nbsp;Like the Covaxin and Covishield vaccine, two doses will be required of Moderna&rsquo;s jab. You would need to get one shot of the vaccine first, and then come back weeks later to get another shot of the vaccine.A huge win for Moderna&rsquo;s vaccine is that it&nbsp;doesn&rsquo;t require extreme cold storage. This will help greatly with shipping logistics and distribution especially&nbsp;in India where temperature is mostly on the higher side.&nbsp;Based on the evidence so far, the new variants of Coronavirus, including the Delta variant first found in India,&nbsp;do not alter the effectiveness of the Moderna mRNA vaccine.&nbsp;

Moderna Covid-19 vaccine approved in India: 5 things to know

With Indian drug regulator giving its nod for the emergency use of vaccine in the country, here are five facts one should know before considering the Moderna&nbsp;vaccine as an option.&nbsp;

Biotech startup Moderna&nbsp;became a leading contender in&nbsp;the production of Covid-19 vaccines last year in November&nbsp;as the&nbsp;results of clinical trials revealed that the vaccine was 94.1% effective in Phase 3 trials.
With Indian drug regulator giving its nod for the emergency use of vaccine in the country, here are five things one should know before considering the Moderna&nbsp;vaccine as an option.&nbsp;
The vaccine developed&nbsp;by Moderna is an mRNA vaccine, which works differently than a typical vaccine. Instead of preventing infection, the vaccine works to teach the body to better fight the virus, lessening its severity.
 Even if the 94.5% efficacy rating, a concern with any vaccine is safety. For Moderna&rsquo;s Covid-19 vaccine, early safety signs are good. Of the participants examined, there have been no major safety concerns reported.&nbsp;
Like the Covaxin and Covishield vaccine, two doses will be required of Moderna&rsquo;s jab. You would need to get one shot of the vaccine first, and then come back weeks later to get another shot of the vaccine.
A huge win for Moderna&rsquo;s vaccine is that it&nbsp;doesn&rsquo;t require extreme cold storage. This will help greatly with shipping logistics and distribution especially&nbsp;in India where temperature is mostly on the higher side.&nbsp;
Based on the evidence so far, the new variants of Coronavirus, including the Delta variant first found in India,&nbsp;do not alter the effectiveness of the Moderna mRNA vaccine.&nbsp;

With Indian drug regulator giving its nod for the emergency use of vaccine in the country, here are five facts one should know before considering the Moderna&nbsp;vaccine as an option.&nbsp;

Biotech startup Moderna&nbsp;became a leading contender in&nbsp;the production of Covid-19 vaccines last year in November&nbsp;as the&nbsp;results of clinical trials revealed that the vaccine was 94.1% effective in Phase 3 trials. With Indian drug regulator giving its nod for the emergency use of vaccine in the country, here are five facts one should know before considering the Moderna&nbsp;vaccine as an option.&nbsp; The vaccine developed&nbsp;by Moderna is an mRNA vaccine, which works differently than a typical vaccine. Instead of preventing infection, the vaccine works to teach the body to better fight the virus, lessening its severity.
 Even if the 94.5% efficacy rating, a concern with any vaccine is safety. For Moderna&rsquo;s Covid-19 vaccine, early safety signs are good. Of the participants examined, there have been no major safety concerns reported.&nbsp; Like the Covaxin and Covishield vaccine, two doses will be required of Moderna&rsquo;s jab. You would need to get one shot of the vaccine first, and then come back weeks later to get another shot of the vaccine. A huge win for Moderna&rsquo;s vaccine is that it&nbsp;doesn&rsquo;t require extreme cold storage. This will help greatly with shipping logistics and distribution especially&nbsp;in India where temperature is mostly on the higher side.&nbsp; Based on the evidence so far, the new variants of Coronavirus, including the Delta variant first found in India,&nbsp;do not alter the effectiveness of the Moderna mRNA vaccine.&nbsp;

German Chancellor Angela Merkel received a Moderna Covid-19 vaccine as her second jab, after getting AstraZeneca as the first, a spokesman said Tuesday.
The 66-year-old took her first dose of AstraZeneca's vaccine in April, more than two weeks after German authorities recommended use of the jab only for people aged 60 and over.
German Chancellor Angela Merkel took her first dose of AstraZeneca's vaccine in April, and on June 22, she received Moderna's Covid-19 vaccine as her second shot
Merkel who is stepping down this year after 16 years in power had sparked concerns for her health in 2019 with a series of shaking spells.

Germany Angela Merkel gets Covid vaccine cocktail, AstraZeneca dose followed by Moderna shot

Covid vaccine cocktail: Angela Merkel gets Moderna as second jab after AstraZeneca first dose

<ul>
<li>German chancellor&nbsp;Angela Merkel&nbsp;gets Covid&nbsp;vaccine cocktail</li>
<li>Merkel receives second&nbsp;Moderna dose after first AstraZeneca shot</li>
<li>Merkel&nbsp;took her first dose of AstraZeneca&nbsp;in April and second dose of Moderna&nbsp;in June</li>
</ul>

German Chancellor Angela Merkel became the first world leader to receive a&nbsp;Covid vaccine cocktail shot.
Merkel took her first dose of AstraZeneca's vaccine in April, and on June 22, she received Moderna's Covid-19 vaccine as her second shot.
The 66-year-old took her first dose of AstraZeneca's vaccine in April, more than two weeks after German authorities recommended the use of the jab only for people aged 60 and over.
Merkel who is stepping down this year after 16 years in power had sparked concerns for her health in 2019 with a series of shaking spells. She has however appeared to be in good condition since then.

US pharma&nbsp;giant&nbsp;Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other drugmakers, PTI has reported. The report said that Cipla has already evinced interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines. Currently, the country is using two "made-in India" jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.

Moderna may launch single-dose Covid vaccine in India next year

US pharma&nbsp;giant&nbsp;Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year

US pharma&nbsp;giant&nbsp;Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other drugmakers, PTI has reported. The report said that Cipla has already evinced interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines. Currently, the country is using two "made-in India" jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.

US firm&nbsp;Moderna said Tuesday its Covid-19 vaccine strongly protects children as young as 12.&nbsp;
But earlier this month, the U.S. and Canada authorized another vaccine - the shot made by Pfizer and BioNTech - to be used starting at age 12.
Moderna aims to be next in line, saying it will submit its teen data to the U.S. Food and Drug Administration and other global regulators early next month.
The company studied more than 3,700 12- to 17-year-olds.With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest to end the pandemic.
&nbsp;

Moderna says its jabs protects kids as young as 12

US firm&nbsp;Moderna said Tuesday its Covid-19 vaccine strongly protects children as young as 12.&nbsp;
But earlier this month, the U.S. and Canada authorized another vaccine - the shot made by Pfizer and BioNTech - to be used starting at age 12.
Moderna aims to be next in line, saying it will submit its teen data to the U.S. Food and Drug Administration and other global regulators early next month.
The company studied more than 3,700 12- to 17-year-olds. With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest to end the pandemic.
&nbsp;

Moderna&nbsp;says&nbsp;Covid-19 vaccine safe for kids as old as 12
US &amp; Canada nod for Pfizer and BioNTech&nbsp;vaccine so far&nbsp;&nbsp;
Moderna&nbsp;sampled 3,700 between 12-17 year-olds

US firm&nbsp;Moderna said Tuesday its Covid-19 vaccine strongly protects children as young as 12.&nbsp;
But earlier this month, the U.S. and Canada authorised another vaccine - the shot made by Pfizer and BioNTech - to be used starting at age 12.
Moderna aims to be next in line, saying it will submit its teen data to the U.S. Food and Drug Administration and other global regulators early next month.
The company studied more than 3,700 12- to 17-year-olds. With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest to end the pandemic.
&nbsp;

The govt may have given the nod to fast track approvals for foreign produced vaccines but will not translate to immediate roll-out of sought after vaccines such as Pfizer, Moderna&nbsp;and J&amp;J. Here is why-:

Pfizer and Moderna&nbsp;both have short-term and long term supply obligations for current production of vaccines
Pfizer and Moderna have supply commitments to at least 12 countries
Pfizer has committed to deliver 200 mn doses to US by July 2021&nbsp;
500 mn Pfizer doses have been committed to the EU by end of 2021&nbsp;
Both US, EU have done a pre-payment of $2 bn, $14.95/dose respectively for the drugs
Moderna has also received $1 billion from the US to deliver 300 million doses by the end of July 2021 and 160 million doses to EU by end of 2021J&amp;J roll-out now faces hurdle due to reports of clots and pause in usage across parts of US


The Vaccine headline is masking the reality! Vaccine wait to continue for Pfizer, Moderna

Pfizer has already committed over 1 billion doses for 2021 between US and EU. Moderna&nbsp;too has contractual agreements across the globe leaving India waiting for it's turn even as approvals get fast tracked.

The Vaccine headline is masking the reality!

The govt may have given the nod to fast track approvals for foreign produced vaccines but will not translate to immediate roll-out of sought after vaccines such as Pfizer, Moderna&nbsp;and J&amp;J. Here is why-:
<ul>
<li>Pfizer and Moderna&nbsp;both have short-term and long term supply obligations for current production of vaccines</li>
<li>Pfizer and Moderna have supply commitments to at least 12 countries</li>
<li>Pfizer has committed to deliver 200 mn doses to US by July 2021&nbsp;</li>
<li>500 mn Pfizer doses have been committed to the EU by end of 2021&nbsp;</li>
<li>Both US, EU have done a pre-payment of $2 bn, $14.95/dose respectively for the drugs</li>
<li>Moderna has also received $1 billion from the US to deliver 300 million doses by the end of July 2021 and 160 million doses to EU by end of 2021 J&amp;J roll-out now faces hurdle due to reports of clots and pause in usage across parts of US</li>
</ul>

moderna vaccines

Categories